Global Transcatheter Embolization And Occlusion Devices Market, By Type (Coil and Non-Coil), By Application (Peripheral Vascular Disease, Oncology, Neurology, and Urology), By End User (Hospitals, Ambulatory Surgical Centers, and Clinics), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

Global  Transcatheter Embolization and Occlusion Devices Market size is expected to be worth around USD 11 Billion by 2032 from USD 5 Billion in 2023, growing at a CAGR of 9.8% during the forecast period from 2023 to 2032.

Transcatheter embolization and occlusion devices allow for the insertion or passage of a synthetic embolus into the body through a specific body part while using a catheter. As part of interventional radiology, transcatheter embolization is a minimally invasive technique used to stop blood flow to malignancies. To identify many strategies to target tumors, synthetic materials are occasionally employed to coat chemotherapeutic medications to carry out simultaneous acts of blood supply blocking and causing cytotoxicity.

The procedures also aid in removing anomalous connections between the veins and arteries and in preventing or controlling aberrant bleeding. The treatment of aneurysms is also aided by it. In addition, unlike open and invasive surgical techniques, transcatheter embolization is particularly effective at controlling bleeding without being invasive.

Key Takeaways

• Market Size: Transcatheter Embolization and Occlusion Devices Market size is expected to be worth around USD 11 Billion by 2032 from USD 5 Billion in 2023.
• Market Growth: The market growing at a CAGR of 9.8% during the forecast period from 2023 to 2032.
• Regional Analysis: The north America is largest market share of 40%, and is expected to register a CAGR of 7.8% during the forecast period.
• Transcatheter Embolization and Occlusion Procedures Are Minimally Invasive: Transcatheter embolization and occlusion procedures can provide minimally invasive solutions by inserting catheters through blood vessels for embolization/occlusion purposes, thus eliminating open surgery procedures while shortening recovery times.
• Clinical Applications: These devices can be utilized in various clinical applications, including embolization of vessels and aneurysm treatment; embolization of uterine fibroids for embolization purposes and arteriovenous malformation management.
• Embolization Materials: Devices typically employ embolic materials to block or reduce blood flow. Common embolic agents include coils, particles, glue and foam.
• Vascular Applications: Transcatheter embolization and occlusion techniques can be utilized in treating various vascular ailments including arterial aneurysms, vein malformations and varicoceles.
• Oncology Applications: These devices can also be utilized in oncology to directly embolize tumor blood vessels or block their access, and therefore target tumors more effectively.
• Gynecological Applications: Uterine Fibroid Embolization is a common procedure utilized in order to address symptoms caused by uterine fibroids.

Type Analysis

Non-Coil Segment of Type Are Expected to be the Dominator in the Market

Based on type, the market for transcatheter embolization and occlusion devices is segmented into coil and non-coil. Among these types, the non-coil segment is the most lucrative in the global transcatheter embolization and occlusion devices market. The usage of these devices has been credited with the quick expansion of this product category since it helps prevent issues including inaccurate deployment, catheter entrapment, and balloon deflation brought on by coiling.

In order to take benefit of the advantages associated with non-coil devices, surgeons are turning more and more toward them. Hence, the market for transcatheter embolization and occlusion devices benefits from the rising demand for illness treatment.

Application Analysis

Neurology Segment is Expected to be the Dominator in the Market

By Application, the market is further divided into peripheral vascular disease, oncology, neurology, urology, and others. The neurology segment is estimated to be the most lucrative segment in the global transcatheter embolization and occlusion devices market, with a market value of US$ 1.54 Bn and a projected CAGR of 7.5%, in 2022.

Also, the oncology segment is estimated to account for US$ 1.2 Bn and a revenue share of 27.4%. Within the oncology field, transcatheter embolization and occlusion devices are primarily used to treat liver cancer, as well as tumors in the kidney, lung, and other parts of the body. These devices are designed to block or reduce blood flow to the tumor, which can shrink the tumor or prevent it from growing further.

End-User Analysis

Hospitals are expected to be the Dominator in the Market

Based on end-user, the market is segmented into hospitals, ambulatory surgical centers, clinics, and others. Among these end-users, the hospital segment is estimated to be the most lucrative segment in the global transcatheter embolization and occlusion devices market, with the largest revenue share of 30.5% and a projected CAGR of 8.5% during the forecast period. The primary reason for hospitals’ dominance in the market is their ability to provide comprehensive medical services, including diagnostics, treatment, and post-treatment care.

Hospitals typically have a wide range of medical specialties and advanced imaging technologies, which are essential for the diagnosis and treatment of complex medical conditions that require transcatheter embolization and occlusion devices. Additionally, hospitals often have the resources and expertise required to handle emergency cases, which can also require the use of these devices. Ambulatory surgery centers (ASCs) and specialty clinics are also important to end users in the market, particularly for procedures that can be performed on an outpatient basis. ASCs and specialty clinics can provide a more convenient and cost-effective alternative to hospital-based care, particularly for patients with less complex conditions.

Key Market Segments

Based on Type

• Coil
  • Pushable Coils
  • Detachable Coils
• Non-Coil
  • Flow Diverting Devices
  • Embolization Particles
  • Liquid Embolics
  • Others

Based on Application

• Peripheral Vascular Disease
• Oncology
• Neurology
• Urology
• Other Applications

Based on End-User

• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Other End-User

Driving Factors

The Usage of These Devices As a Less Painful Alternative to Open Surgery Drives the Market

A synthetic embolus is positioned or inserted into the blood vessel using a tiny catheter during transcatheter embolization and occlusion (TEO), a minimally invasive (MI) procedure used to stop blood flow to the tumor or other parts of the body. The global burden of chronic diseases has led to a large growth in the transcatheter embolization and occlusion devices market. In order to identify many strategies to target tumors, synthetic compounds are occasionally employed to coat chemotherapeutic medications, performing simultaneous activities of blood supply blocking and producing cytotoxicity.

The procedures also aid in removing improper connections between the veins and arteries and in preventing or controlling abnormal bleeding. Moreover, it aids in the management of aneurysms. Also, there has been a rise in the usage of these devices as a less painful alternative to open surgery with smaller incisions. The Global Transcatheter Embolization and Occlusion Devices Market are projected to grow as a result of these technological developments in the industry.

Restraining Factors

High Cost And Lack of Skilled Professionals Are the Reason for Restraint

The transcatheter embolization and occlusion devices market has been growing steadily in recent years, driven by the increasing adoption of minimally invasive techniques and the rising incidence of various medical conditions that require these devices. However, there are also several factors such as High cost, Lack of skilled professionals, Regulatory hurdles, Competition from alternative treatments, and Adverse events that could act as restraints on the growth of the market.

However, ongoing innovation and improvements in device technologies, along with efforts to increase access to skilled professionals and reduce costs, are likely to continue driving growth in the market in the coming years.

Growth Opportunities

AI And Robotics Are Being Used More In Healthcare, Even During Minimally Invasive Treatments

In the upcoming years, the market for transcatheter embolization and occlusion devices is anticipated to present a number of opportunities due to the rising demand for minimally invasive procedures and ongoing advancements in device technology. Devices for transcatheter embolization and occlusion are being created and investigated for new indications and uses, including the treatment of uterine fibroids and prostate cancer.

These new applications can widen the market and give device makers more chances to present cutting-edge fixes. AI and robotics are being used more and more in healthcare, even during minimally invasive treatments. Robotics and AI could be used in conjunction with transcatheter embolization and occlusion devices to enhance accuracy and results while opening up new business prospects for device producers.

Overall, due to continued innovation and rising demand for minimally invasive procedures, the transcatheter embolization and occlusion devices market is anticipated to present a number of opportunities in the years to come. Device makers who can create cutting-edge, secure, and efficient products will be well-positioned to seize these opportunities and increase their market share.

Trending Factors

Rising Demand for Minimally Invasive Procedures is the main reason For the usage of these devices

The transcatheter embolization and occlusion devices market is undergoing several key trends that are shaping the market landscape.  Transcatheter embolization and occlusion procedures are minimally invasive, which means they offer several advantages over traditional surgical techniques. Patients generally experience less pain, shorter hospital stays, and quicker recovery times. This has led to increasing adoption of these procedures, particularly in developed countries. Cardiovascular and oncology conditions are some of the leading causes of death worldwide.

As the global population continues to age and lifestyles continue to change, the prevalence of these conditions is expected to increase. This is driving demand for transcatheter embolization and occlusion devices, which are used to treat a range of conditions in these areas.

Regional Analysis

North America is expected to be the dominant region in the market

North America is estimated to be the most lucrative market in the global transcatheter embolization and occlusion devices market, with the largest market share of 40%, and is expected to register a CAGR of 7.8% during the forecast period. The market is driven by the growing prevalence of chronic diseases such as cancer, heart diseases, and neurological disorders, as well as the increasing adoption of minimally invasive procedures. The presence of well-established healthcare infrastructure and high healthcare expenditure also contribute to market growth.

However, Europe is the second-largest market for transcatheter embolization and occlusion devices, with Germany, France, and the United Kingdom being the largest contributors to the market. The region is driven by the increasing incidence of chronic diseases, the growing aging population, and the presence of advanced healthcare facilities. Overall, the transcatheter embolization and occlusion devices market is driven by a combination of demographic, epidemiological, and healthcare-related factors. The market dynamics vary by region, with some regions experiencing faster growth than others.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

The transcatheter embolization and occlusion devices market is highly competitive, the major players in the market account for a significant share of the global market. In 2021, Boston Scientific Corporation, Medtronic, and Stryker Corporation were identified as the leading players in the transcatheter embolization and occlusion devices market, together accounting for a significant share of the market.

These key players are focusing on product innovation and new product launches to maintain their market position. For instance, in 2021, Boston Scientific Corporation launched its new Embolization Particle, Embozene TANDEM Microspheres, for the treatment of hypervascular tumors. Similarly, in 2020, Stryker Corporation launched the CrossBoss Coronary CTO Crossing Catheter, an advanced atherectomy device used for the treatment of chronic total occlusions.

Overall, the market for transcatheter embolization and occlusion devices is expected to remain competitive and continue to grow as new and innovative products are introduced to the market.

Listed below are some of the most prominent transcatheter embolization and occlusion devices industry players.

Market Key Players

• Boston Scientific Corporation
• Terumo Corporation
• Medtronic, Inc.
• DePuy Synthes
• Stryker Corporation
• Cordis Corporation
• Jude Medical
• Pfizer, Inc.
• Sirtex Medical
• Nordian
• Other Key Players

Recent Developments

• Boston Scientific Corporation: On January 8, 2024, Boston Scientific announced its acquisition of Axonics, Inc., a move aimed at expanding its urology portfolio with differentiated technologies. This acquisition is set to enhance their offerings in the market for devices treating urinary and bowel dysfunction​.
• Medtronic, Inc.: Medtronic completed the acquisition of Affera on August 30, 2022. This strategic move expanded Medtronic’s cardiac ablation portfolio to include a novel cardiac mapping and navigation platform, marking its entry into integrated diagnostic solutions for cardiac procedures
• Stryker Corporation: Stryker launched the PROstep MIS Lapidus on September 19, 2023, introducing a new minimally invasive surgical option for treating bunions. This launch underscores Stryker’s commitment to advancing minimally invasive technologies in the surgical space​.

Report Scope